{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T17:00:04Z","timestamp":1756573204233,"version":"3.40.5"},"reference-count":24,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Cryopyrin-Associated Periodic Syndrome (CAPS) is a variety of clinical\nvariants of autoinflammatory diseases. The pathology is based on a mutation in the NLRP3 gene\nencoding the cryopyrin protein, which leads to the uncontrolled production of interleukin-1\u03b2. Particular\nattention should be paid to the rarity of this disease and the lack of clinical knowledge about\nit in therapeutic and rheumatological practice, which leads to an erroneous diagnosis and the appointment\nof ineffective treatment for a long time, leading to the progression of the disease and disability\nof the patient.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation:<\/jats:title>\n<jats:p>This article describes a clinical case of this disease. The first manifestations of\nthe disease in a woman appeared from the age of 2 years, in the form of a rash and fever. Since\nschool age, there have been signs of arthritis. By the age of 24, sensorineural hearing loss and pain\nin the spine were evident. The disease occurred under the clinical manifestations of spondyloarthritis.\nIts treatment with anti-inflammatory therapy did not give a stable result.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>From the analysis, we can conclude that patient M. from early childhood suffers from\na severe Neonatal-onset Multisystem Inflammatory Disease of a genetic nature. For a long time,\nthe patient was diagnosed with ankylosing spondylitis, and appropriate treatment was carried out\nwithout significant success. The correct diagnosis of CAPS was made only in 2018. This patient\nhas conditions of both CAPS and AS together, which is a very rare association in rheumatological\npractice. The only treatment method that could stop the manifestations of the disease and prevent\nlife-threatening kidney damage (amyloidosis) is the use of genetically engineered biological drugs,\ni.e., IL-1\u03b2 inhibitors. The only drug of this group registered in Russia is canakinumab (Ilaris\u00ae).\nFrom the moment of diagnosis to the present day, the patient is treated with the genetically engineered\ndrug canakinumab (Ilaris\u00ae) at a dose of 150 mg once every 8 weeks. 6 months after taking\nthe drug, the patient went into complete clinical and laboratory remission.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397117666211116110833","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T04:43:25Z","timestamp":1637124205000},"page":"373-379","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rare Clinical Case of Cryopyrin-associated Periodic Syndrome Presented\nwith Ankylosing Spondylitis: A Case Report"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-2883","authenticated-orcid":true,"given":"Shanmugaraj","family":"Kulanthaivel","sequence":"first","affiliation":[{"name":"Science and Research Department, Naarayani Multi Speciality Hospital, Kavindapadi,\nErode, Tamilnadu, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9147-8461","authenticated-orcid":true,"given":"Anna A.","family":"Zayaeva","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyudmila V.","family":"Sokolova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3609-792X","authenticated-orcid":true,"given":"Denis V.","family":"Shaduro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6398-2545","authenticated-orcid":true,"given":"Andrey V.","family":"Petrov","sequence":"additional","affiliation":[{"name":"Department\nof Immunology and Biological Therapy, Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University,\nSimferopol, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-3190","authenticated-orcid":true,"given":"Vitalii B.","family":"Kaliberdenko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine No.2, V.I. Vernadsky Crimean Federal University, Simferopol, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00393-017-0271-y","volume":"76","author":"K&#xFC;mmerle-Deschner JB","year":"2017","unstructured":"K&#xFC;mmerle-Deschner JB; Lohse P; Genetics of cryopyrin-associated periodic syndrome. Z Rheumatol 2017,76(4),313-321","journal-title":"Z Rheumatol"},{"key":"ref=2","first-page":"45","volume":"13","author":"Kozlova A.L.","year":"2014","unstructured":"Kozlova A.L.; Mamzerova E.S.; Novichkova G.A.; Shherbina A.; Clinical manifestations and therapy of cryopyrin-associated periodic fever syndromes. Pediatr Hematol \/Oncol Immunopathol 2014,13,45-49","journal-title":"Pediatr Hematol \/Oncol Immunopathol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11882-010-0160-9","volume":"11","author":"Yu J.R.","year":"2011","unstructured":"Yu J.R.; Leslie K.S.; Cryopyrin-associated periodic syndrome: An update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011,11(1),12-20","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref=4","first-page":"92","volume":"75","author":"Fietta P.","year":"2004","unstructured":"Fietta P.; Autoinflammatory diseases: The hereditary periodic fever syndromes. Acta Biomed 2004,75(2),92-99","journal-title":"Acta Biomed"},{"key":"ref=5","first-page":"43","volume":"2","author":"Barabanova O.V.","year":"2007","unstructured":"Barabanova O.V.; Konopljova E.A.; Prodeus A.P.; Shherbina A.; Periodicheskie sindromy. Trudnyj pacient Available from: 2007,2,43-50","journal-title":"Trudnyj pacient"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.immuni.2009.04.012","volume":"30","author":"Meng G.","year":"2009","unstructured":"Meng G.; Zhang F.; Fuss I.; Kitani A.; Strober W.; A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009,30(6),860-874","journal-title":"Immunity"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/JIR.S51250","volume":"8","author":"Ozaki E.","year":"2015","unstructured":"Ozaki E.; Campbell M.; Doyle S.L.; Targeting the NLRP3 inflammasome in chronic inflammatory diseases: Current perspectives. J Inflamm Res 2015,8,15-27","journal-title":"J Inflamm Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/rheumatology\/40.5.579","volume":"40","author":"Frenkel J.","year":"2001","unstructured":"Frenkel J.; Houten S.M.; Waterham H.R.; Wanders R.J.; Rijkers G.T.; Duran M.; Kuijpers T.W.; van Luijk W.; Poll-The B.T.; Kuis W.; Clinical and molecular variability in childhood periodic fever with hyperimmunoglobulinaemia D. Rheumatology (Oxford) 2001,40(5),579-584","journal-title":"Rheumatology (Oxford)"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1067\/mai.2001.118790","volume":"108","author":"Hoffman H.M.","year":"2001","unstructured":"Hoffman H.M.; Wanderer A.A.; Broide D.H.; Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001,108(4),615-620","journal-title":"J Allergy Clin Immunol"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.15690\/vsp.v12i1.558","volume":"12","author":"Gattorno M.","year":"2013","unstructured":"Gattorno M.; Cryopyrin-associated periodic syndrome. Questions of Modern Pediatrics 2013,12(1)","journal-title":"Questions of Modern Pediatrics"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"Lachmann H.J.","year":"2009","unstructured":"Lachmann H.J.; Kone-Paut I.; Kuemmerle-Deschner J.B.; Leslie K.S.; Hachulla E.; Quartier P.; Gitton X.; Widmer A.; Patel N.; Hawkins P.N.; Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009,360(23),2416-2425","journal-title":"N Engl J Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/1574887115666200917110954","volume":"16","author":"Kulanthaivel S.","year":"2021","unstructured":"Kulanthaivel S.; Kaliberdenko V.B.; Balasundaram K.; Shterenshis M.V.; Scarpellini E.; Abenavoli L.; Tocilizumab in SARS-CoV-2 patients with the syndrome of cytokine storm: A narrative review. Rev Recent Clin Trials 2021,16(2),138-145","journal-title":"Rev Recent Clin Trials"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1056\/NEJM200306193482523","volume":"348","author":"Hawkins P.N.","year":"2003","unstructured":"Hawkins P.N.; Lachmann H.J.; McDermott M.F.; Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003,348(25),2583-2584","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1002\/art.22842","volume":"56","author":"Gattorno M.","year":"2007","unstructured":"Gattorno M.; Tassi S.; Carta S.; Delfino L.; Ferlito F.; Pelagatti M.A.; D\u2019Osualdo A.; Buoncompagni A.; Alpigiani M.G.; Alessio M.; Martini A.; Rubartelli A.; Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007,56(9),3138-3148","journal-title":"Arthritis Rheum"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1759720X13502629","volume":"5","author":"Kuemmerle-Deschner J.B.","year":"2013","unstructured":"Kuemmerle-Deschner J.B.; Haug I.; Canakinumab in patients with cryopyrin-associated periodic syndrome: An update for clinicians. Ther Adv Musculoskelet Dis 2013,5(6),315-329","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/art.41004","volume":"71","author":"Brogan P.A.","year":"2019","unstructured":"Brogan P.A.; Hofer M.; Kuemmerle-Deschner J.B.; Kon&#xE9;-Paut I.; Roesler J.; Kallinich T.; Horneff G.; Calvo Penad&#xE9;s I.; Sevilla-Perez B.; Goffin L.; Lauwerys B.R.; Lachmann H.J.; Uziel Y.; Wei X.; Laxer R.M.; Rapid and sustained long-term efficacy and safety of canakinumab in patients with cryopyrin-associated periodic syndrome ages five years and younger. Arthritis Rheumatol 2019,71(11),1955-1963","journal-title":"Arthritis Rheumatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1517\/14712598.2010.530653","volume":"10","author":"Feist E.","year":"2010","unstructured":"Feist E.; Burmester G.R.; Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opin Biol Ther 2010,10(11),1631-1636","journal-title":"Expert Opin Biol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1001\/archderm.136.12.1487","volume":"136","author":"Toro J.R.","year":"2000","unstructured":"Toro J.R.; Aksentijevich I.; Hull K.; Dean J.; Kastner D.L.; Tumor necrosis factor receptor-associated periodic syndrome: A novel syndrome with cutaneous manifestations. Arch Dermatol 2000,136(12),1487-1494","journal-title":"Arch Dermatol"},{"key":"ref=19","first-page":"302","volume":"31","author":"Imagawa T.","year":"2013","unstructured":"Imagawa T.; Nishikomori R.; Takada H.; Takeshita S.; Patel N.; Kim D.; Lheritier K.; Heike T.; Hara T.; Yokota S.; Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013,31(2),302-309","journal-title":"Clin Exp Rheumatol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"Braun J.","year":"2011","unstructured":"Braun J.; van den Berg R.; Baraliakos X.; Boehm H.; Burgos-Vargas R.; Collantes-Estevez E.; Dagfinrud H.; Dijkmans B.; Dougados M.; Emery P.; Geher P.; Hammoudeh M.; Inman R.D.; Jongkees M.; Khan M.A.; Kiltz U.; Kvien T.; Leirisalo-Repo M.; Maksymowych W.P.; Olivieri I.; Pavelka K.; Sieper J.; Stanislawska-Biernat E.; Wendling D.; Ozgocmen S.; van Drogen C.; van Royen B.; van der Heijde D.; 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011,70(6),896-904","journal-title":"Ann Rheum Dis"},{"year":"2010","key":"ref=21","unstructured":"Rheumatology: Clinical guidelines \/ edited by the academician of RAMS E.L. Nasonova. Available from: 2010"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14412\/1996-7012-2014-4-17-24","volume":"8","author":"Salugina S.O.","year":"2014","unstructured":"Salugina S.O.; Fedorov E.S.; Kuz'mina N.N.; Zakharova E.Y.; The interleukin -1 inhibitor canakinumab in the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS): Clinical experience. Sovremennaya Revmatologiya 2014,8(4),17-24","journal-title":"Sovremennaya Revmatologiya"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2147\/BTT.S3167","volume":"2","author":"Church L.D.","year":"2008","unstructured":"Church L.D.; Savic S.; McDermott M.F.; Long term management of patients with Cryopyrin-Associated Periodic Syndromes (CAPS): Focus on rilonacept (IL-1 Trap). Biologics 2008,2(4),733-742","journal-title":"Biologics"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/17512433.2017.1338946","volume":"10","author":"Landmann E.C.","year":"2017","unstructured":"Landmann E.C.; Walker U.A.; Pharmacological treatment options for cryopyrin-associated periodic syndromes. Expert Rev Clin Pharmacol 2017,10(8),855-864","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397117666211116110833","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197955\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573397117666211116110833","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T07:03:38Z","timestamp":1669100618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197955\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397117666211116110833","relation":{},"ISSN":["1573-3971"],"issn-type":[{"type":"print","value":"1573-3971"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}